<DOC>
	<DOCNO>NCT00075725</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , dexamethasone , prednisone , methotrexate , leucovorin calcium ( LCV ) , work different way stop cancer cell divide stop grow die . Giving one drug may kill cancer cell . It yet know combination chemotherapy regimen effective treat acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial study dexamethasone see well work compare prednisone induction therapy . This trial also study methotrexate leucovorin calcium see well work compare methotrexate alone maintenance therapy treat patient newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Dexamethasone Compared With Prednisone During Induction Therapy MTX With Without Leucovorin During Maintenance Therapy Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare outcome patient high-risk acute lymphoblastic leukemia treat 2 different chemotherapy regimen . - Compare relative safety efficacy dexamethasone v prednisone induction therapy patient treat regimen . - Compare relative safety efficacy high-dose methotrexate leucovorin rescue v escalate methotrexate without leucovorin rescue interim maintenance I patient treat regimen . - Correlate minimal residual disease ( MRD ) day 29 event-free survival overall survival patient treat regimen . - Correlate early marrow response status day-29 MRD patient treat regimen . - Identify additional high-risk patient treatment fully augment Berlin-Frankfurt-Munster regimen use day-29 MRD . OUTLINE : This randomize , multicenter study . Patients stratify accord early response ( slow early response ( SER ) v rapid early response ( RER ) . - Induction therapy : Patients randomize 1 4 treatment arm . - Arm I : Patients receive intrathecal ( IT ) cytarabine day 1 ; vincristine ( VCR ) IV daunorubicin IV day 1 , 8 , 15 , 22 ; oral IV dexamethasone twice daily day 1-14 ; IT methotrexate ( MTX ) day 8 29* ; pegaspargase intramuscularly ( IM ) day 4 , 5 , 6 . Note : *Patients CNS3 disease ( WBC &gt; 5/mL cerebrospinal fluid positive blast cytospin ) also receive IT MTX day 15 22 . - Arm II : Patients receive induction therapy arm I . - Arm III : Patients receive cytarabine , vincristine , daunorubicin , pegaspargase ( PEG-ASP ) arm I . Patients also receive oral IV prednisone twice daily day 1-28 IT MTX day 8 29 . - Arm IV : Patients receive induction therapy arm III . Patients arm evaluate day 29 induction therapy . Patients M3 disease remove study . Patients M1 disease le 1 % minimal residual disease ( MRD ) proceed consolidation therapy begin day 36 . Patients M2 disease OR M1 disease least 1 % MRD receive extend induction therapy 2 additional week . Patients SER disease MLL rearrangements remove study may eligible treatment protocol COG-AALL0031 . - Extended induction therapy : Patients continue receive therapy arm originally randomize . - Arms I II : Patients receive oral IV dexamethasone twice daily day 1-14 ; vincristine IV day 1 8 ; daunorubicin IV day 1 ; pegaspargase IM day 4 , 5 , 6 reevaluate . - Arms III IV : Patients receive oral IV prednisone twice daily day 1-14 , vincristine , daunorubicin , pegaspargase arm I II reevaluate . Patients arm M1 disease le 1 % MRD extend induction proceed consolidation therapy continue SER patient . All patient remove study . - Consolidation therapy : All patient receive cyclophosphamide IV 30 minute day 1 29 ; cytarabine IV subcutaneously ( SC ) day 1-4 , 8-11 , 29-32 , 36-39 ; oral mercaptopurine ( MP ) day 1-14 29-42 ; vincristine IV day 15 , 22 , 43 , 50 ; pegaspargase IM day 15 43 ; IT MTX* day 1 , 8 , 15 , 22 . Patients testicular disease also receive radiotherapy testis . NOTE : *Patients CNS3 disease receive MTX day 1 8 . - Interim maintenance therapy I : Patients continue receive treatment arm originally randomize . - Arm I ( escalating-dose MTX ) : Patients receive vincristine IV escalating-dose MTX IV day 1 , 11 , 21 , 31 , 41 ; pegaspargase IM day 2 22 ; IT MTX day 1 21 . - Arm II ( high-dose MTX ) : Patients receive vincristine IV high-dose methotrexate IV 24 hour day 1 , 15 , 29 , 43 ; oral MP day 1-56 ; IT MTX day 1 29 . Patients also receive leucovorin calcium IV every 6 hour least 3 dos , begin 42 hour start MTX infusion . - Arm III ( escalating-dose MTX ) : Patients receive interim maintenance I therapy arm I . - Arm IV ( high-dose MTX ) : Patients receive interim maintenance I therapy arm II . - Delayed intensification therapy I : All patient receive vincristine IV day 1 , 8 , 15 , 43 , 50 ; oral IV dexamethasone twice daily day 1 21 patient age 1 12 OR day 1-7 15-21 patient age 13 ; doxorubicin IV day 1 , 8 , 15 ; pegaspargase IM day 4 , 5 , 6 AND day 43 ; cyclophosphamide IV 30 minute day 29 ; cytarabine IV SC day 30-33 37-40 ; oral thioguanine day 29-42 ; IT MTX day 1 , 29 , 36 . After delayed intensification I , SER patient proceed interim maintenance II delay intensification II . RER patient proceed directly maintenance . - Interim maintenance therapy II : All patient receive vincristine IV MTX IV day 1 , 11 , 21 , 31 , 41 ; pegaspargase IM day 2 22 ; IT MTX day 1 21 . Patients proceed delay intensification II . - Delayed intensification therapy II : All patient receive therapy delay intensification I , arm I. CNS3 patient also receive radiotherapy 3-10 day , begin day 29 . All SER patient , patient MLL rearrangement , patient pretreated steroid ( &gt; 48 hour within week prior diagnosis ) receive prophylactic cranial radiotherapy ( CRT ) 8 day , begin day 29 . Patients proceed maintenance therapy . - Maintenance therapy : All patient receive vincristine IV day 1 , 29 , 57 ; oral dexamethasone twice daily day 1-5 , 29-33 , 57-61 ; oral MP day 1-84 ; IT MTX day 1* ; oral MTX day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 . NOTE : *RER ( undergo CRT ) patient also receive IT MTX day 29 maintenance course 1-4 . In arm , maintenance therapy repeat every 12 week total duration therapy 2 year start interim maintenance I female patient 3 year start interim maintenance I male patient . Patients testicular disease may receive testicular radiotherapy 8 day one first 3 course maintenance therapy . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 2,964 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose Bprecursor acute lymphoblastic leukemia WBC &gt; 50,000/mm^3 patient age 1 9 Any WBC patient age 10 30 OR patient receive prior steroid therapy OR patient testicular disease Must eligible enrol classification study COGAALL03B1 PATIENT CHARACTERISTICS : Age 1 31 Performance status Not specify Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No 72 hour since prior intrathecal cytarabine No prior cytotoxic chemotherapy Endocrine therapy Prior steroid allow Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
</DOC>